← Leaderboards
Shenda Baker
Synedgen, Inc.
$4,633,100
Attributed
$5,531,421
Total exposure
8
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.8M · FY2009–22$2M$1.5M$1M$500K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$5,531,421 · 8
By mechanism
R44$3,760,469 · 2
U01$1,078,629 · 1
R43$495,616 · 4
N43$196,707 · 1
Top collaborators
- Robert Gallotto1 shared
Others in their field
Top investigators on “Dose”
- Lawrence Corey · Fred Hutchinson Cancer Center$251,944,397
- Sharon A Nachman · Johns Hopkins University$213,337,729
- David Heimbrook · Leidos Biomedical Research, Inc.$146,807,554
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$134,297,561
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$124,321,134
- Peter C Adamson · National Childhood Cancer Foundation$122,197,823
Research focus
DoseExcisionInfectionInflammationLeadPreventIn VivoSurfaceIn VitroMucous MembraneResponseAnti-Inflammatory AgentsLesionHealingInjuryInflammatoryBiological MarkersPhysiologicalPharmaceutical PreparationsAntibioticsBaseAnimalsCellsTopical Application
Grant awards (13)
A novel highly stable pancreatic enzyme replacement therapy to improve outcomes for patients with pancreatic insufficiency.$1,796,643
R44 · FY2022 · DK
Identification of lead compounds to topically treat sulfur mustard injury to reduce ocular damage and improve vision.$33,733
U01 · FY2022 · EY · contact PI
Identification of lead compounds to topically treat sulfur mustard injury to reduce ocular damage and improve vision.$319,250
U01 · FY2021 · EY · contact PI
Identification of lead compounds to topically treat sulfur mustard injury to reduce ocular damage and improve vision.$321,965
U01 · FY2020 · EY · contact PI
Identification of lead compounds to topically treat sulfur mustard injury to reduce ocular damage and improve vision.$74,526
U01 · FY2020 · EY · contact PI
Identification of lead compounds to topically treat sulfur mustard injury to reduce ocular damage and improve vision.$329,155
U01 · FY2019 · EY · contact PI
Prevention and treatment of GI obstruction syndromes in cystic fibrosis$146,412
R43 · FY2015 · DK · contact PI
Novel Topical Radioprotector for Gl Mucosal Exposure$196,707
N43 · FY2014 · CA · contact PI
Mucolytic for enhanced mucus and biofilm clearance in cystic fibrosis patients$149,901
R43 · FY2013 · HL · contact PI
Antimicrobial and Regenerative Treatment for Oral Mucositis$970,980
R44 · FY2012 · DE · contact PI
Antimicrobial and Regenerative Treatment for Oral Mucositis$992,846
R44 · FY2011 · DE · contact PI
Wound Decontamination for the Prevention and Treatment of Multi-drug Resistant Ba$99,638
R43 · FY2010 · AI · contact PI
Prevention and Treatment of Oral Biofilms and Related Oral Disease by Soluble Chi$99,665
R43 · FY2009 · DE · contact PI